© The Financial Times Ltd 2015 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Mar 21, 2015, the consensus forecast amongst 5 polled investment analysts covering CTI BioPharma Corp advises investors to purchase equity in the company. This has been the consensus forecast since the sentiment of investment analysts improved on Mar 18, 2015. The previous consensus forecast advised that CTI BioPharma Corp would outperform the market.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 4 analysts offering 12 month price targets for CTI BioPharma Corp have a median target of 5.50, with a high estimate of 8.00 and a low estimate of 3.50. The median estimate represents a 194.12% increase from the last price of 1.87. View Full Financials
Dividend information is not available for CTi Biopharma Corp. View Full Financials
On Mar 12, 2015, CTI BioPharma Corp reported 4th quarter 2014 losses of -0.140 per share. This result exceeded the -0.18 consensus loss of the 3 analysts covering the company and under-performed last year's 4th quarter results by -0.22.
The next earnings announcement is expected on Apr 27, 2015. View Full Interim Financials
|Average growth rate||+5.00 %|
CTI BioPharma Corp reported annual 2014 losses of -0.49 per share on Mar 12, 2015. View Full Annual Financials
|Average growth rate||+38.73 %|
CTI BioPharma Corp. had 4th quarter 2014 revenues of 17.7890m. This bettered the 2.4745m consensus of the 2 analysts covering the company. This was 55.00 % below the prior year's 4th quarter results. View Full Interim Financials
|Average growth rate||+738.81 %|
CTI BioPharma Corp. had revenues for the full year 2014 of 60.0770m. This was 2,496.24% above the prior year's results. View Full Annual Financials
|Average growth rate||+798.75 %|